Dihydroergotamine: role in the treatment of migraine

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.5, Iss.9, 2009-09, pp. : 1141-1148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

By Silberstein Stephen

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 13, 2012-09 ,pp. : 1961-1968

Informa Healthcare

Access to resources Recommend Favorite

Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

By Morren John A Galvez-Jimenez Nestor

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3085-3093

Informa Healthcare

Access to resources Recommend Favorite

Role of Melatonin in the Pathophysiology of Migraine: Implications for Treatment

By Vogler Barbara Rapoport Alan M. Tepper Stewart J. Sheftell Fred Bigal Marcelo E.

CNS Drugs, Vol. 20, Iss. 5, 2006-01 ,pp. : 343-350

Adis International

Access to resources Recommend Favorite

The PROMISE Study: PROphylaxis of MIgraine with SEglor ® (Dihydroergotamine Mesilate) in French Primary Care

By André Pradalier

CNS Drugs, Vol. 18, Iss. 15, 2004-01 ,pp. : 1149-1163

Adis International

Access to resources Recommend Favorite

Treatment of migraine with prophylactic drugs

By Evers Stefan

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2565-2573

Informa Healthcare

Access to resources Recommend Favorite